Discover
BNTC
Benitec Biopharma Inc.
12.69
2 x 9.56
2 x 16.30
bid
ask
-
0.69
5.16%
2 @ 04:00 PM
12.69 +0.00 (0.00%)
| Ytd | -5.79% | |
| 1y | 4.79% |
12.66
day range
13.49
9.85
52 week range
16.76
| Open | 13.26 | Prev Close | 13.38 | Low | 12.66 | High | 13.49 | Mkt Cap | 435.96M |
| Vol | 114.52K | Avg Vol | 115.41K | EPS | -0.93 | P/E | N/A | Forward P/E | -1.23 |
| Beta | 0.88 | Short Ratio | 1.35 | Inst. Own | 82.59% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-14 | 50-d Avg | 11.81 | 200-d Avg | 12.52 | 1yr Est | 25.43 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2025-02-11 | 2024-12 | -1 | N/A | N/A | N/A |
| 2024-11-14 | 2024-09 | -0.61 | -0.48 | 0.13 | 21.31% |
| 2024-09-26 | 2024-06 | -0.58 | N/A | N/A | N/A |
| 2024-05-13 | 2024-03 | 0 | -1.64 | N/A | N/A |
| 2024-02-13 | 2023-12 | 0 | -2.64 | N/A | N/A |
| 2023-11-13 | 2023-09 | 0 | -2.76 | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-12-13 | Baird | Upgrade | Outperform | |
| 2024-12-03 | Guggenheim | Upgrade | Buy | Buy |
| 2024-07-22 | Leerink Partners | Upgrade | Outperform | |
| 2024-06-13 | Piper Sandler | Upgrade | Overweight | |
| 2024-04-22 | JMP Securities | Upgrade | Market Outperform | Market Outperform |
| 2024-02-15 | JMP Securities | Upgrade | Market Outperform | Market Outperform |
Profile
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. Benitec Biopharma Inc. was incorporated in 1995 and is headquartered in Hayward, California.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2023-08-10 | BOSTON MEGAN JOAN | Officer and Director | 25.93K | Purchase |
| 2023-08-10 | BUCHI J. KEVIN | Director | 52.10K | Purchase |
| 2024-12-02 | SUVRETTA CAPITAL MANAGEMENT, LLC | Director and Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Suvretta Capital Management, LLC | 8.83M | 102.24M | 38.03% |
| 2024-09-29 | Janus Henderson Group PLC | 876.52K | 10.15M | 3.78% |
| 2024-09-29 | Adage Capital Partners GP L.L.C. | 841.40K | 9.74M | 3.62% |
| 2024-09-29 | Nantahala Capital Management, LLC | 838.10K | 9.71M | 3.61% |
| 2024-09-29 | Franklin Resources, Inc. | 796.64K | 9.23M | 3.43% |
| 2024-09-29 | AWM Investment Company, Inc. | 625.00K | 7.24M | 2.69% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-07-30 | Franklin Strategic Series-Franklin Biotechnology Discove | 573.22K | 6.64M | 2.47% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 207.79K | 2.41M | 0.90% |
| 2024-09-29 | Simplify Exchange Traded Fds-Health Care ETF | 116.54K | 1.35M | 0.50% |
| 2024-10-30 | Fidelity Extended Market Index Fund | 47.68K | 552.13K | 0.21% |
| 2024-10-30 | Fidelity Total Market Index Fund | 15.67K | 181.45K | 0.07% |
| 2024-10-30 | Fidelity Series Total Market Index Fund | 11.40K | 131.98K | 0.05% |
Dividend
| Dividend | Date |
|---|---|
| 0.002929 | 2018-06-01 |
Split
| Split | Date |
|---|---|
| 1 : 17 | 2023-07-26 |
| 2 : 3 | 2020-04-15 |
| 1 : 10 | 2019-11-18 |
| 1 : 4 | 2015-06-16 |